On May 31, 2013, interim data from the company’s Phase II pancreatic cancer study were published in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois. For more information, see http://abstracts2.asco.org/AbstView_132_115489.html.
